<DOC>
	<DOCNO>NCT01771276</DOCNO>
	<brief_summary>The purpose study help find Primary Obesity Surgery Endoluminal ( POSE ) procedure make patient feel less hungry fuller faster , lead weight loss . In study , USGI Medical want see stomach empty gastro-intestinal hormone level change POSE procedure increase ( compare typical ) number anchor place .</brief_summary>
	<brief_title>ULTIMATE Study Weight Loss</brief_title>
	<detailed_description>This study use USGI Medical Incisionless Operating Platform ( IOP ) determine affect place Suture Anchors per patient ( compare current practice ) Primary Obesity Surgery Endoluminal ( POSE ) . USGI want see place anchor ( particularly distal body/antrum region ) significantly impact primary weight loss , satiety , metabolic outcome .</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<criteria>Has BMI &gt; 30 &lt; 40 Male female â‰¥21 yr . age &lt; 60 yr . age time enrollment Patient significant weight change ( +/ 5 % total body weight ) last 6 month able lose significant weight past diet exercise . Is reasonable candidate general anesthesia Agrees additional weight loss interventional procedure liposuction least 18 month follow study enrollment agrees take prescription counter weight loss medication least 1 year . Physically mentally able comply visit schedule , ancillary testing , behavior modification ( diet exercise ) require study agrees study commitment requirement Had successful completion prescreening , nutritional educational program psychological assessment support subject appropriate bariatric surgical candidate History ( intraoperative evidence ) bariatric , gastric esophageal surgery Esophageal stricture anatomy and/or condition could preclude passage endolumenal instrument Moderate severe Gastroesophageal reflux disease ( GERD ) Known hiatal hernia &gt; 3cm history determine UGI exam endoscopy Known GI motility disorder pancreatic insufficiency/disease Intraoperative Exclusion : Active peptic ulcer hiatal hernia &gt; 3cm Pregnancy . Present Corticosteroid Use History inflammatory disease GI tract Severe coagulopathies , hepatic insufficiency cirrhosis History present use insulin insulin derivative treatment diabetes Had Type II Diabetes Mellitus ( define HgbA1c &gt; 6.0 ) great 2 year time enrollment Uncontrolled Type II DM ( HgbA1c &gt; 7.0 screening ) Patient quit smoking within last 6 month time enrollment plan quit smoke next year Patient history drug alcohol abuse actively abuse either Patient presently treat medication depression , psychosis , mood eat disorder Nonambulatory significant impairment mobility Works , first degree relative investigator , study institution , support staff involve study . Known hormonal genetic cause obesity Participating another clinical study Patient medication know impact GI motility gut hormone discontinue prior nuclear test Have work hour , family obligation transportation issue could interfere patient return scheduled evaluation , test nutritional counseling . Lives &gt; 60 kilometer investigator site . Patient able provide write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>POSE</keyword>
</DOC>